Proctological and Perineal Surgical Unit, Department of Gastroenterology, Cisanello University Hospital, Pisa, Italy.
Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.
Tech Coloproctol. 2018 Jan;22(1):53-58. doi: 10.1007/s10151-017-1696-7. Epub 2017 Oct 23.
In recent years, stapled transanal resection (STARR) has been adopted worldwide with convincing short-term results. However, due to the high recurrence rate and some major complications after STARR, there is still controversy about when the procedure is indicated. The aim of this study was to assess the safety, efficacy and feasibility of STARR performed with a new dedicated device for tailored transanal stapled surgery.
All the consecutive patients affected by obstructed defecation syndrome (ODS) due to rectocele or/and rectal intussusception, who underwent STARR with the TST STARR-Plus stapler, were included in a prospective study. Pain, Cleveland Clinic Score for Constipation (CCCS) and incontinence, patient satisfaction, number of hemostatic stitches, operative time, hospital stay and perioperative complications were recorded. Postoperative complications and recurrence were also reported.
Forty-five consecutive patients (median age 50; range 24-79) were included in the study. Median resected volume was 15 cm (range 12-19 cm) with a median height of surgical specimen of 5.6 cm (range 4.5-10 cm). The mean CCCS decreased from 17.26 (± 3.77) to 5.42 (± 2.78) postoperatively (p < 0.001). Patient satisfaction grade was excellent in 14 patients (31.1%), good in 25 (55.5%), sufficient in three (6.7%) and poor in three patients (6.7%). No major complications occurred. Five patients (11%) reported urgency after 30 days and two patients (4%) after 12 months. The Cleveland Clinic Incontinence score did not significantly change. At a median follow-up of 23 months (range 12-30 months), only three patients (6.7%) reported recurrent symptoms of obstructed defecation comparable to those reported at baseline.
TST STARR-Plus seems to be safe and effective for the treatment of ODS due to rectocele and rectal intussusception, and technical improvement could reduce the risk of some complications. However, careful patient selection is still the best means of preventing complications.
近年来,吻合器经肛直肠切除术(STARR)已在全球范围内应用,并取得了令人信服的短期疗效。然而,由于 STARR 术后复发率较高且存在一些重大并发症,其适应证仍存在争议。本研究旨在评估一种新型专用经肛吻合器(TST STARR-Plus)行经肛吻合直肠切除术(STARR)的安全性、疗效和可行性。
所有因直肠前突或/和直肠套叠导致出口梗阻型便秘(ODS)的连续患者,均采用 TST STARR-Plus 吻合器行 STARR 术,前瞻性研究记录疼痛、克利夫兰便秘评分(CCCS)、失禁、患者满意度、止血缝线数量、手术时间、住院时间和围手术期并发症。还报告了术后并发症和复发情况。
共纳入 45 例连续患者(中位年龄 50 岁;范围 24-79 岁)。中位切除体积为 15cm(范围 12-19cm),手术标本高度为 5.6cm(范围 4.5-10cm)。术后 CCCS 从 17.26(±3.77)降至 5.42(±2.78)(p<0.001)。14 例(31.1%)患者满意度评级为优秀,25 例(55.5%)为良好,3 例(6.7%)为满意,3 例(6.7%)为不满意。无重大并发症发生。30 天后 5 例(11%)患者出现急迫感,12 个月后 2 例(4%)患者出现急迫感。克利夫兰失禁评分无显著变化。中位随访 23 个月(范围 12-30 个月),仅 3 例(6.7%)患者报告复发性 ODS 症状与基线时相似。
TST STARR-Plus 治疗直肠前突和直肠套叠所致 ODS 安全有效,技术改进可降低某些并发症的风险。但仔细选择患者仍是预防并发症的最佳手段。